Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Revenue Per Share for the year ending December 31, 2023

Cyteir Therapeutics Inc Revenue Per Share is NA for the year ending December 31, 2023. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Cyteir Therapeutics Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Cyteir Therapeutics Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Cyteir Therapeutics Inc Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Cyteir Therapeutics Inc Revenue Per Share for the year ending December 31, 2019 was USD 0.00.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends